SCTbio

Executive Summary

SCTbio is a privately held contract development and manufacturing organization (CDMO) based in Brno, Czech Republic, specializing in cell and gene therapies. Founded in 2016 and backed by the PPF Group, the company offers comprehensive services from process development to cGMP manufacturing for cell-based products and retroviral vectors. As the demand for advanced therapies grows, SCTbio is well-positioned to capitalize on the expanding outsourcing market in Europe. Its strategic location, technical expertise, and strong financial backing provide a stable platform for growth, though the company faces competition from larger, established CDMOs. With no disclosed pipeline or financials, SCTbio's near-term performance will depend on its ability to secure new client contracts and expand its manufacturing capabilities.

Upcoming Catalysts (preview)

• Q4 2026Completion of new cGMP manufacturing facility expansion70% success
• Q2 2026Major client contract win with a top-20 pharma company50% success
• Q3 2026Certification for lentiviral vector manufacturing80% success